Management of Tremor
Start with propranolol or primidone as first-line pharmacotherapy for essential tremor, as these are effective in up to 70% of patients; when medical therapy fails or is contraindicated, proceed directly to surgical intervention with deep brain stimulation (DBS) for adjustability or MRI-guided focused ultrasound (MRgFUS) thalamotomy for a minimally invasive option. 1
Algorithmic Treatment Approach
Step 1: Initiate Treatment Only When Functionally Necessary
Treatment should begin only when tremor interferes with quality of life or functional activities—management is symptomatic, not curative 1. Essential tremor causes greater impairment than Parkinson's disease in writing, eating, drinking, and social activities 1.
Step 2: First-Line Pharmacotherapy
- Propranolol (the only FDA-approved medication for essential tremor) 2
- Primidone
- Both achieve efficacy in approximately 70% of patients 1
- Topiramate at doses >200 mg/day is also clinically useful 3
Common pitfall: Beta-blockers like propranolol are contraindicated in patients with chronic obstructive pulmonary disease or certain cardiac conditions 1. Screen for these comorbidities before prescribing.
Step 3: Second-Line Pharmacotherapy (Less Effective)
- Gabapentin
- Carbamazepine
- Alprazolam (possibly useful) 3
- These are notably less effective than first-line agents 1
Step 4: Surgical Intervention When Medical Therapy Fails
Proceed to surgery when pharmacotherapy shows:
- Lack of efficacy
- Dose-limiting side effects
- Medical contraindications
- Occupational restrictions 1
Surgical Options (All Target VIM Thalamus)
Deep Brain Stimulation (DBS)
- Primary advantage: Adjustable parameters allow optimization of therapeutic window while minimizing adverse effects 4
- Unilateral VIM thalamic DBS is classified as possibly useful 3
- FDA-approved since 1997 2
- Bilateral interventions are increasingly feasible 4
MRI-Guided Focused Ultrasound (MRgFUS) Thalamotomy
- Key advantage: Incisionless, minimally invasive procedure 1
- FDA-approved in 2016 2
- Tremor improvement: 56% sustained at 2 years and 4 years 1
- Disability improvement: 63% at 4 years 1
- Safety profile: No hemorrhage or infection risk (unlike open procedures); serious adverse events rare (1.6%) 1
- Early adverse effects (gait disturbance 36%, paresthesias 38%) mostly resolve by 1 year (reduced to 9% and 14% respectively) 1
Contraindications for MRgFUS:
- Cannot undergo MRI
- Skull density ratio <0.40 1
Alternative Surgical Options
- Radiofrequency thalamotomy: Viable for patients ineligible for DBS or MRgFUS 4
- Gamma Knife radiosurgery: Another alternative with comparable efficacy 4
Treatment Selection Strategy
Choose DBS when: Patient needs adjustability, bilateral treatment, or has concerns about permanent lesioning
Choose MRgFUS when: Patient prefers minimally invasive approach, wants to avoid hardware implantation, or has unilateral dominant tremor
Choose RF thalamotomy or radiosurgery when: Patient is ineligible for DBS or MRgFUS 4
Special Considerations
Parkinson's Disease Tremor
Parkinsonian tremor is often refractory to dopaminergic medications despite bradykinesia and rigidity responding well 5. Consider levodopa, anticholinergics, or dopaminergic agonists first, then proceed to DBS or MRgFUS if refractory 5.
Head and Voice Tremor
Botulinum toxin type A injections are possibly useful for these specific tremor types 3, 2, though evidence remains limited.
Emerging Technologies
Noninvasive transcutaneous afferent patterned stimulation devices have FDA approval but require further study 2. Force-controlling strategies and peripheral neuromodulation show promise but face limitations in wearability and clinical translation 6.
Critical Evidence Strength Note
The MRgFUS recommendation is based on a single randomized, sham-surgery-controlled, double-blind trial with sustained 4-year follow-up data 1. Direct comparative studies between surgical modalities are lacking and unlikely to be performed due to differences in patient selection and preferences 1.